Cargando…
Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituxima...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445827/ https://www.ncbi.nlm.nih.gov/pubmed/22889180 http://dx.doi.org/10.1186/1756-8722-5-49 |
_version_ | 1782243867395883008 |
---|---|
author | Kim, Yu Ri Kim, Jin Seok Min, Yoo Hong Yoon, Dok Hyun Shin, Ho-Jin Mun, Yeung-Chul Park, Yong Do, Young Rok Jeong, Seong Hyun Park, Joon Seong Oh, Sung Yong Lee, Suee Park, Eun Kyung Jang, Joung-Soon Lee, Won-Sik Lee, Hwe-Won Eom, HyeonSeok Ahn, Jae-sook Jeong, Jae-Heon Baek, Sun Kyung Kim, Seok Jin Kim, Won Seog Suh, Cheolwon |
author_facet | Kim, Yu Ri Kim, Jin Seok Min, Yoo Hong Yoon, Dok Hyun Shin, Ho-Jin Mun, Yeung-Chul Park, Yong Do, Young Rok Jeong, Seong Hyun Park, Joon Seong Oh, Sung Yong Lee, Suee Park, Eun Kyung Jang, Joung-Soon Lee, Won-Sik Lee, Hwe-Won Eom, HyeonSeok Ahn, Jae-sook Jeong, Jae-Heon Baek, Sun Kyung Kim, Seok Jin Kim, Won Seog Suh, Cheolwon |
author_sort | Kim, Yu Ri |
collection | PubMed |
description | BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. RESULTS: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). CONCLUSIONS: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value. |
format | Online Article Text |
id | pubmed-3445827 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34458272012-09-20 Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) Kim, Yu Ri Kim, Jin Seok Min, Yoo Hong Yoon, Dok Hyun Shin, Ho-Jin Mun, Yeung-Chul Park, Yong Do, Young Rok Jeong, Seong Hyun Park, Joon Seong Oh, Sung Yong Lee, Suee Park, Eun Kyung Jang, Joung-Soon Lee, Won-Sik Lee, Hwe-Won Eom, HyeonSeok Ahn, Jae-sook Jeong, Jae-Heon Baek, Sun Kyung Kim, Seok Jin Kim, Won Seog Suh, Cheolwon J Hematol Oncol Research BACKGROUND: The objective of this study was to identify prognostic factors for survival in patients with primary diffuse large B-cell lymphoma (DLBCL) of the adrenal gland. METHODS: Thirty one patients diagnosed with primary adrenal DLBCL from 14 Korean institutions and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were analyzed. RESULTS: Complete remission (CR) and overall response rate after R-CHOP chemotherapy were 54.8% and 87.0%. The 2-year estimates of overall survival (OS) and progression-free survival (PFS) were 68.3% and 51.1%. In patients achieving CR, significant prolongations of OS (P = 0.029) and PFS (P = 0.005) were observed. Ann Arbor stage had no influence on OS. There was no significant difference in OS between patients with unilateral involvement of adrenal gland and those with bilateral involvement. When staging was modified to include bilateral adrenal involvement as one extranodal site, early stage (I or II) significantly correlated with longer OS (P = 0.021) and PFS (P <0.001). CONCLUSIONS: Contrary to prior reports, our data suggests that outcomes of primary adrenal DLBCL are encouraging using a regimen of R-CHOP, and that achieving CR after R-CHOP is predictive of survival. Likewise, our modified staging system may have prognostic value. BioMed Central 2012-08-13 /pmc/articles/PMC3445827/ /pubmed/22889180 http://dx.doi.org/10.1186/1756-8722-5-49 Text en Copyright ©2012 Kim et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kim, Yu Ri Kim, Jin Seok Min, Yoo Hong Yoon, Dok Hyun Shin, Ho-Jin Mun, Yeung-Chul Park, Yong Do, Young Rok Jeong, Seong Hyun Park, Joon Seong Oh, Sung Yong Lee, Suee Park, Eun Kyung Jang, Joung-Soon Lee, Won-Sik Lee, Hwe-Won Eom, HyeonSeok Ahn, Jae-sook Jeong, Jae-Heon Baek, Sun Kyung Kim, Seok Jin Kim, Won Seog Suh, Cheolwon Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) |
title | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) |
title_full | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) |
title_fullStr | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) |
title_full_unstemmed | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) |
title_short | Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) |
title_sort | prognostic factors in primary diffuse large b-cell lymphoma of adrenal gland treated with rituximab-chop chemotherapy from the consortium for improving survival of lymphoma (cisl) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3445827/ https://www.ncbi.nlm.nih.gov/pubmed/22889180 http://dx.doi.org/10.1186/1756-8722-5-49 |
work_keys_str_mv | AT kimyuri prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT kimjinseok prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT minyoohong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT yoondokhyun prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT shinhojin prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT munyeungchul prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT parkyong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT doyoungrok prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT jeongseonghyun prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT parkjoonseong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT ohsungyong prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT leesuee prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT parkeunkyung prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT jangjoungsoon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT leewonsik prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT leehwewon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT eomhyeonseok prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT ahnjaesook prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT jeongjaeheon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT baeksunkyung prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT kimseokjin prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT kimwonseog prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl AT suhcheolwon prognosticfactorsinprimarydiffuselargebcelllymphomaofadrenalglandtreatedwithrituximabchopchemotherapyfromtheconsortiumforimprovingsurvivaloflymphomacisl |